Review: Immune-mediated necrotizing myopathies - a heterogeneous group of diseases with specific myopathological features

Neuropathology and Applied Neurobiology

Volumn 38, Issue 7, 2012, Pages 632-646

  Stenzel, W ^a   Goebel, H H ^a,b   Aronica, E ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Autoantibodies; Immune mediated; Inflammation; Necrosis; Necrotizing myopathy; Toxic myopathies

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE SYNTHASE; PRAVASTATIN; RITUXIMAB; SIGNAL RECOGNITION PARTICLE; SIMVASTATIN;

ADVERSE DRUG REACTION; ANTISYNTHETASE SYNDROME; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DYSARTHRIA; DYSPHAGIA; ELECTROMYOGRAPHY; ELECTRON MICROSCOPE; ENDOPLASMIC RETICULUM; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC DISEASE; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MACROPHAGE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE DISEASE; MYALGIA; MYOSITIS; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PHAGOCYTOSIS; POLYMYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MUSCLE, SKELETAL; MUSCULAR DISEASES; NECROSIS;

EID: 84869132294     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2012.01302.x     Document Type: Review

References (76)

1. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7: 343-354
2. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-2766
3. Arlet JB, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier FJ, Bloch-Queyrat C, Goulvestre C, Heshmati F, Atassi M, Guillevin L, Herson S, Benveniste O, Mouthon L. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16: 334-336
4. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65: 1635-1638
5. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 209-215
6. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420-428
7. Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, Saez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 1009-1016
8. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62: 1328-1334
9. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 2009; 48: 594-595
10. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-721
11. Danko K, Ponyi A, Molnar AP, Andras C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol 2009; 21: 594-598
12. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50: 764-767
13. Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011; 23: 612-619
14. Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17: 404-408
15. Wegener S, Bremer J, Komminoth P, Jung HH, Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol 2010; 3: 88-92
16. Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011; 40: 249-255
17. Dimitri D, Eymard B. Inflammatory myopathies, autoimmune necrotizing myopathies and adult-onset genetic myopathies: differential diagnosis. Rev Med Interne 2012; 33: 134-142
18. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347
20. Targoff IN, Miller FW, Medsger TA, Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527-535
21. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208
22. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-1498
23. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713
24. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337-345
25. Vosskamper M, Korf B, Franke F, Schachenmayr W. Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis. J Neurol 1989; 236: 489-490
26. Smith B. Skeletal muscle necrosis associated with carcinoma. J Pathol 1969; 97: 207-210
27. Urich H, Wilkinson M. Necrosis of muscle with carcinoma: myositis or myopathy? J Neurol Neurosurg Psychiatry 1970; 33: 398-407
28. Yutani C, Matsuda Y, Murao S, Kamo Y, Yoshida H, Nakajima T. Necrotizing myopathy as a remote effect of gastric cancer accompanied with Hashimoto's thyroiditis. Acta Pathol Jpn 1978; 28: 165-174
29. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41: 936-939
30. Hervier B, Uzunhan Y, Hachulla E, Benveniste O, Nunes H, Delaval P, Musset L, Dubucquoi S, Wallaert B, Hamidou M. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 2011; 37: 714-717
31. Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, Camara B, Fournie B, Couret B, Hatron PY, Dubucquoi S, Hamidou M. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010; 49: 972-976
32. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22: 633-638
33. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35: 389-395
34. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 1986; 83: 9507-9511
35. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361-1370
36. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116-123
37. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, Amoura Z, Marie I, Guiguet M, Eymard B, Gilbert D, Tron F, Herson S, Musset L, Boyer O. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63: 1961-1971
38. Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin JA. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol 1987; 138: 3219-3223
39. Hanisch F, Muller T, Stoltenburg G, Zierz S. Unusual manifestations in two cases of necrotizing myopathy associated with SRP antibodies. Rheumatol Int 2011; DOI: 10.1007/s00296-011-2311-2
40. Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, Kawai M, Ishihara T, Suzuki N, Kuwana M. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008; 47: 1539-1542
41. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210
42. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72
43. Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012; 12: 54-61
44. Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009; 22: 506-515
45. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35
46. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17: 194-200
47. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008; 359: 789-799
48. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690
49. Wahl D, Petitpain N, Frederic M, Bour S, Kaminsky P, Trechot P. Myopathy associated with statin therapy. Neuromuscul Disord 2007; 17: 661-662
50. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2012; 41: 185-190
51. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000; 12: 475-481
52. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135: 1550-1556
53. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, Zen M, Vattemi GA, Lundberg IE, Doria A. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010; 49: 2370-2374
54. Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993; 100: 116-123
55. Hengstman GJ, Ter Laak HJ, van Engelen BG, van Venrooij BG. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001; 70: 706
56. Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001; 13: 476-482
57. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, Loy AC, Chan EK, Reeves WH, Satoh M. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54: 2004-2009
58. Gelpi C, Kanterewicz E, Gratacos J, Targoff IN, Rodriguez-Sanchez JL. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996; 39: 692-697
59. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, Song YW, Mimori T, Targoff IN. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007; 56: 1295-1303
60. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol 2008; 14: 285-288
61. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006; 73: 646-654
62. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68: 472-478
63. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22: 668-674
64. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A. Anti-Mi-2 antibodies. Autoimmunity 2005; 38: 79-83
65. Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65: 242-245
66. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25-28
67. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66: 1345-1349
68. Ueyama H, Kumamoto T, Araki S. Circulating autoantibody to muscle protein in a patient with paraneoplastic myositis and colon cancer. Eur Neurol 1992; 32: 281-284
69. Silvestre J, Santos L, Batalha V, Del Rio A, Lima C, Carvalho A, Martins A, Miranda H, Cabral F, Felix A, Aleixo A. Paraneoplastic necrotizing myopathy in a woman with breast cancer: a case report. J Med Case Rep 2009; 3: 95
70. Galani E, Bonakis A, Christodoulou C, Klouvas G, Drougou A, Skarlos D. Can cetuximab affect paraneoplastic myopathy? J Neurooncol 2009; 93: 437-438
71. Hocar O, Poszepczynska-Guigne E, Faye O, Wechsler J, Bagot M, Buffard V. [Severe necrotizing myopathy subsequent to Merkel cell carcinoma]. Ann Dermatol Venereol 2011; 138: 130-134
72. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011; 23: 595-604
73. Samuels N, Applbaum YH, Esayag Y. Paraneoplastic necrotizing myopathy and dermatomyositis in a patient with rectosigmoid carcinoma. Rheumatol Int 2011; DOI: 10.1007/s00296-011-2304-1
74. Authier FJ, Kondo H, Ghnassia RT, Revuz J, Gherardi RK. Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology 1996; 46: 1448-1451
75. Reimann J, Kornblum C, Tolksdorf K, Bruck W, van Landeghem FK. Myopathy and neuropathy with pipestem capillaries and vascular activated complement deposition. Neurology 2011; 77: 401-403
76. Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol 2011; 178: 1279-1286